Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAPDH | P04406 | 2/20 | 0.78 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.78 |
| ▸ | NADK | O95544 | 1/20 | 0.75 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.68 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.68 |
| ▸ | TRPM2 | O94759 | 3/20 | 0.62 |
| ▸ | HSPA5 | P11021 | 3/20 | 0.58 |
| ▸ | SLC28A2 | O43868 | 5/20 | 0.57 |
| ▸ | HSPA8 | P11142 | 3/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | AMD1 | P17707 | 2/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL954614 | 1.00 | GAPDH (0.78) | GAPDHHSD17B10NADKSIRT2SIRT1 | |
| SCHEMBL1097445 | 0.88 | GAPDH (1.00) | GAPDHHSD17B10NADKSIRT2SIRT1 | |
| SCHEMBL15906322 | 0.88 | GAPDH (1.00) | GAPDHHSD17B10NADKSIRT2SIRT1 | |
| SCHEMBL1106676 | 0.88 | GAPDH (1.00) | GAPDHHSD17B10NADKSIRT2SIRT1 | |
| SCHEMBL13835108 | 0.88 | GAPDH (0.84) | GAPDHHSD17B10NADKSIRT2SIRT1 | |
| SCHEMBL1097451 | 0.88 | GAPDH (1.00) | GAPDHHSD17B10NADKSIRT2SIRT1 | |
| SCHEMBL952181 | 0.87 | GAPDH (0.83) | GAPDHHSD17B10NADKSIRT2SIRT1 | |
| SCHEMBL952182 | 0.87 | GAPDH (0.83) | GAPDHHSD17B10NADKSIRT2SIRT1 | |
| SCHEMBL954252 | 0.87 | AMD1 (0.72) | GAPDHHSD17B10NADKHSPA5HSPA8 | |
| SCHEMBL954255 | 0.87 | AMD1 (0.72) | GAPDHHSD17B10NADKHSPA5HSPA8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009354-A1 | 5',-SUBSTITUTED ADENOSYNES PREPARATION THEREOF AND USE AS INHIBITORS OF S-ADENOSYLMETHIONINE DECARBOXYLASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-13 | — | — | US | claimed |
| EP-2170057-A1 | 5'-SUBSTITUTED ADENOSYNES, PREPARATION THEREOF AND USE AS INHIBITORS OF S-ADENOSYLMETHIONINE DECARBOXYLASE | Southern Research Institute (US) | 2010-04-07 | — | — | EP | claimed |
| WO-2009018541-A1 | 5'-SUBSTITUTED ADENOSYNES, PREPARATION THEREOF AND USE AS INHIBITORS OF S-ADENOSYLMETHIONINE DECARBOXYLASE | SOUTHERN RESEARCH INSTITUTE (US) | 2009-02-05 | — | — | WO | claimed |
| US-8637485-B2 | 5′,-substituted adenosynes preparation thereof and use as inhibitors of S-adenosylmethionine decarboxylase | SOUTHERN RESEARCH INSTITUTE (US) | 2014-01-28 | — | — | US | disclosed |
| EP-2574616-A2 | 5'-substituted adenosynes, preparation thereof and use as inhibitors of s-adenosylmethionine decarboxylase. | Southern Research Institute (US) | 2013-04-03 | — | — | EP | disclosed |
| US-20110009354-A1 | 5',-SUBSTITUTED ADENOSYNES PREPARATION THEREOF AND USE AS INHIBITORS OF S-ADENOSYLMETHIONINE DECARBOXYLASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-13 | — | — | US | disclosed |
| EP-2170057-A1 | 5'-SUBSTITUTED ADENOSYNES, PREPARATION THEREOF AND USE AS INHIBITORS OF S-ADENOSYLMETHIONINE DECARBOXYLASE | Southern Research Institute (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009018541-A1 | 5'-SUBSTITUTED ADENOSYNES, PREPARATION THEREOF AND USE AS INHIBITORS OF S-ADENOSYLMETHIONINE DECARBOXYLASE | SOUTHERN RESEARCH INSTITUTE (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009354-A1 | 5',-SUBSTITUTED ADENOSYNES PREPARATION THEREOF AND USE AS INHIBITORS OF S-ADENOSYLMETHIONINE DECARBOXYLASE | AMD1, ADA, MTAP | GAPDH 1209/4885HSD17B10 330/4885NADK 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.